Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04979052
Other study ID # HDM-FUN-Candidemia
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 31, 2022
Est. completion date January 2025

Study information

Verified date January 2023
Source Radboud University Medical Center
Contact Frank vd Veerdonk, Dr.
Phone 0031243618819
Email frank.vandeveerdonk@radboudumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia.


Description:

A multi-center open label adaptive randomized interventional phase 2 study to evaluate safety and efficacy of rIFN-y treatment in patiens with candidemia. Patients will be randomized 1:1 between intervention (rIFN-y immunotherapy, subcutaneous dose of 100miicrogram thrice weekly for two weeks or until hospital discharge) in addition to standard of care versus controls (standard of care). Standard of care antifungal therapy is according to ESCMID/EFISG (Europe) or IDSA (US) guidelines. We will assess the effect on clinical outcome and investigate relevant biomarkers that can guide this immunotherapeutic approach.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males or non-pregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline). - Subjects who are 18 years of age or older. - Subjects with at least one positive blood culture isolation of Candida species from a specimen drawn within 120 hours prior to study entry. - Subjects who have clinical evidence of infection sometime within 120 hours prior to enrolment, including at least one of the following: - Temperature >37.8 °C on two occasions at least four hours apart or one measurement > 38.2 °C - Systolic blood pressure <90 or a >30 mmHg decrease in systolic blood pressure from the subject's normal baseline or the need for vassopressive therapy. - Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida (e.g. joint, skin, eye, bone, oesophagus). - Radiologic findings of invasive candidiasis. - Subject or their legal representative must sign a written informed consent form. - In case a patient eligible to participate in this study is incapacitated and as such unable to personally provide informed consent, a written consent form must be signed by their legal representative. - Only incapacitated patients that can be expected to regain the capability to consent will be included in this study. In this case, informed consent will be discussed personally with the study participant after recovery. - The inclusion of incapacitated subjects will only be performed under the above conditions in a country in which such an approach is legal and deemed ethically acceptable. Exclusion Criteria: - Subjects with a history of allergy or intolerance to rIFN-?,or any other IMP ingredient or with a history of immediate type hypersensitivity to latex/rubber. - Subjects with a history of documented epileptic seizures. - Subjects with severe liver failure ((>5x upper limit AST or ALT or impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time). - Treatment with heterologous serum proteins, or immunological preparations such as vaccines, toxins, serums and allergens within three days before trial enrolment. - Women who are pregnant or lactating. - Subjects who are unlikely to survive more than 24 hours. - Subjects who have failed previous systemic antifungal therapy for the Candida spp. infection which is being studied. - Subjects who have received more than 120 hours of systemic antifungal therapy for the current episode, within 120 hours prior to study entry. - With respect to incapacitated subjects: - Any patient that is deemed incapable of personally providing informed consent due to a neurodegenerative disease, genetic syndrome, and/or perinatal asphyxia, will not be eligible for inclusion in this trial. - Any incapacitated subject that is not expected to recover to a point where they will personally be able to provide informed consent will not be eligible for inclusion in this trial. Patients with renal failure or dialysis do not have a contraindication for treatment with rIFN-y and can be included in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Interferon Gamma-1B
100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.

Locations

Country Name City State
Germany Klinikum Der Johann Wolfgang Von Goethe Universitaet Frankfurt am main
Greece Hellenic Institute for the Study of Sepsis (HISS) Athens
Netherlands Radboudumc Nijmegen Gelderland
Romania Universitatea de Medicina si Farmacie luliu Hatieganu Cluj-Napoca
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne
United States Duke University Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Radboud University Medical Center Horizon 2020 - European Commission

Countries where clinical trial is conducted

United States,  Germany,  Greece,  Netherlands,  Romania,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to first negative blood culture Day 14
Secondary Time to treatment success microbiological eradication of Candida from the blood and any other site of infection; resolution of fever; resolution of other diagnostic variables, such as imaging results, where applicable; and no new signs of infection. The time at which all the variables are met is defined as the date of resolution of infection. Day 14
Secondary Percentage of patients with mycological outcomes through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
Secondary Percentage of patients with treatment success through intervention completion, an average at day 11 and 2 and 4 weeks after intervention completion
Secondary Overall survival Study day 28
Secondary Number of patients with Treatment Emergent Adverse Events (TEAEs). Study day 49
Secondary Sequential Organ Failure Assessment (SOFA) score Study day 14
Secondary Adverse events Study day 14
Secondary Body weight kg Study day 49
Secondary BMI kg/m^2 Study day 49
Secondary Prealbumin mg/dl Study day 49
Secondary Total lymphocytes 10^9/L Study day 49
Secondary Cholesterol mmol/L Study day 49
See also
  Status Clinical Trial Phase
Terminated NCT01982071 - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia Phase 4
Completed NCT02163889 - Serial Therapeutic and Antifungal Monitoring Protocol
Completed NCT02244606 - Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis Phase 2
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Not yet recruiting NCT01249313 - Risk Factor and Outcome of Candidemia N/A
Completed NCT00940017 - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Phase 4
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT00105144 - Study of Micafungin in Patients With Invasive Candidiasis or Candidemia Phase 3
Completed NCT03667690 - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Phase 3
Completed NCT03604705 - An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia Phase 2
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Recruiting NCT04147975 - Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
Completed NCT01734525 - Negative Beta Glucan in ICU Patients Phase 4
Withdrawn NCT01622595 - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients N/A
Completed NCT03363841 - Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) Phase 3
Completed NCT03799172 - Echinocandins Versus Azoles for Candidemia Treatment
Completed NCT01406093 - Early- and Late-onset Candidemia N/A
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Completed NCT00113191 - Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants N/A